LMAT - LeMaitre Vascular - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5255582018

Vascular Grafts, Catheters, Patches, Shunts, Biosynthetic Grafts, Medical Tapes

LeMaitre Vascular, Inc. is a leading developer, manufacturer, and marketer of medical devices and implants used in vascular surgery worldwide. The company's product portfolio includes a range of innovative solutions designed to improve patient outcomes and enhance surgical procedures.

One of the company's key offerings is its human cadaver tissue cryopreservation services, which provide surgeons with access to high-quality tissue for use in various vascular procedures. Additionally, LeMaitre Vascular offers a range of catheters, including angioscopes, embolectomy catheters, thrombectomy catheters, occlusion catheters, and perfusion catheters, which are used to visualize, remove blood clots, and restore blood flow in arteries and veins.

The company's biologic grafts and patches are also an essential part of its product lineup. These include the artegraft biologic graft, a bovine carotid artery used for dialysis access, as well as XenoSure, VascuCel, and CardioCel biologic patches, which are used for vessel repair, heart repair and reconstruction, and neonatal repairs. LeMaitre Vascular's cardiovascular patches and carotid shunts are also designed to facilitate complex vascular procedures.

In addition to these products, the company offers a range of innovative solutions, including biosynthetic vascular grafts, vascular grafts, and radiopaque tape, which enables surgeons to locate tributaries or lesions beneath the skin. Valvulotomes, which are used to cut or disrupt valves in the saphenous vein, and closure systems, which attach vessels to one another with titanium clips, are also part of the company's product portfolio.

LeMaitre Vascular markets its products through a direct sales force and distributors, providing surgeons and healthcare professionals with access to its innovative solutions. With a strong commitment to innovation and customer satisfaction, the company has established itself as a leader in the vascular surgery market.

Headquartered in Burlington, Massachusetts, LeMaitre Vascular, Inc. was founded in 1983 and has a rich history of innovation and growth. The company's website, https://www.lemaitre.com, provides further information on its products, services, and mission to improve patient outcomes in vascular surgery.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for LMAT - LeMaitre Vascular  - Stock Price & Dividends

LMAT Stock Overview

Market Cap in USD 1,979m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 2006-10-19

LMAT Stock Ratings

Growth 5y 81.5
Fundamental 77.7
Dividend 55.0
Rel. Performance vs Sector 4.45
Analysts 4.22/5
Fair Price Momentum 110.16 USD
Fair Price DCF 35.18 USD

LMAT Dividends

Dividend Yield 12m 0.68%
Yield on Cost 5y 1.83%
Dividends CAGR 5y 10.49%
Payout Consistency 100.0%

LMAT Growth Ratios

Growth 12m 87.94%
Growth Correlation 12m 98%
Growth Correlation 3m 71.1%
CAGR 5y 21.48%
CAGR/Mean DD 5y 1.40
Sharpe Ratio 12m 2.47
Alpha vs SP500 12m 51.95
Beta vs SP500 5y weekly 0.93
ValueRay RSI 31.20
Volatility GJR Garch 1y 34.72%
Price / SMA 50 1.22%
Price / SMA 200 19.41%
Current Volume 60.5k
Average Volume 20d 105.4k

External Links for LMAT Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of LMAT stocks?
As of October 18, 2024, the stock is trading at USD 89.69 with a total of 60,467 shares traded.
Over the past week, the price has changed by +0.46%, over one month by +0.98%, over three months by +3.91% and over the past year by +83.82%.
What are the forecast for LMAT stock price target?
According to ValueRays Forecast Model, LMAT LeMaitre Vascular will be worth about 122 in October 2025. The stock is currently trading at 89.69. This means that the stock has a potential upside of +35.99%.
Issuer Forecast Upside
Wallstreet Target Price 95.8 6.76
Analysts Target Price 67.9 -24.3
ValueRay Target Price 122 36.0